High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers

By afschroeder • August 9, 2025

Ennin E, Mallepally N, Ali M, Shojaie L, Dewberry S, Trieu M, Torres ETR, Zhou K, Kahn J, Dodge JL, Dara L. High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers. Liver Int. 2025 Sep;45(9):e70255. doi: 10.1111/liv.70255. PMID: 40778804.

Tags: CTLA‐4, Digestive Diseases, Fellow, ILICI, immune‐related adverse events, immunotherapy, liver injury, PD‐1, Publications

Liver Metabolomic Profiling Reveals Distinct Signatures Between Steatosis and Metabolic Dysfunction-Associated Steatohepatitis

Palomurto S, Flam E, Kaminska D, Virtanen KA, Kärjä V, Käkelä P, Pajukanta P, Eberlé D, Haas JT, Raverdy V, Caiazzo R, Pattou F, Staels[...]

Medications for Alcohol Use Disorder Among Patients With Severe Alcohol-Related Liver Disease

Sundaresh R, Singh J, Meza J, Saab S, Shetty A. Medications for Alcohol Use Disorder Among Patients With Severe Alcohol-Related Liver Disease. JAMA Netw Open.[...]

Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis

Lewis S, Wildman-Tobriner B, Cuevas J, Calle S, Bolger I, Wang K, Joshi H, Mankowski Gettle L, Yang JD, Min JH, Sirlin CB, Reeder SB,[...]